Prescribility of generic microemulsion Cyclosporine A in heart transplant patients

• Autor(a) principal: Manrique,Ricardo
• Data de Publicação: 2003
• Outros Autores: Magalhães,Hélio M., Dinkhuysen,Jarbas, Correia,Edileide, Lin-Wang,Hui Tsu, Vasconcellos,Marcos, Carvalho,Eliete, Mejia,Juan A. C., Souza Neto,João D de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Cardiovascular Surgery (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382003000200008
• topic: Cyclosporine/pharmacokinetics; Cyclosporine/toxicity; Cyclosporine/therapeutic use; Immunossupressives; Heart transplantation

OBJECT: This paper aims to define the prescribility (therapeutic efficacy and bio-safety) of generic microemulsion Cyclosporin (Sigmasporin Microral®). METHOD: Casuistic: Twenty heart transplantation patients, 13 males and 7 females, with a mean age of 49.6 years, began immunosuppression treatment with generic microemulsion cyclosporin (Sigmasporin Microral®). They underwent clinical and laboratory evaluation during a minimum of three months. Procedures included clinic evaluation with electro and echocardiogram, endomyocardial biopsy, routine biochemical and hematological tests. RESULTS: The mean follow-up was 10 months with a maximum of 16 months. A total of 151 endomyocardial biopsies were evaluated: 31.7% were degree 0, 43.7% 1a and 23.1% 1b. We had only one case of acute clinical rejection confirmed by biopsy as IIIa, and one patient with mediastinitis, both of whom had a good evolution. The mean cyclosporin blood level was 303 Ng/mL. All other parameters also showed a good evolution. CONCLUSION: Generic microemulsion cyclosporin (Sigmasporin Microral®) shows therapeutic efficacy and an excellent bio-safety profile. Its Prescribility is confirmed.